DUBLIN--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma in 2018 - The Patient Perspective - The Views of 27 Patient Groups with an Interest in Bleeding Disorders" report has been added to ResearchAndMarkets.com's offering.
- The views of 27 patient groups specialising in bleeding disorders (94% in haemophilia).
- Drawn from a November 2018-February 2019 survey.
Eight companies analysed in this report: Bayer - CSL Behring - Grifols - Novo Nordisk - Octapharma - Pfizer - Roche (Genentech in the US) - Takeda/Shire.
How bleeding-disorders patient groups view the pharmaceutical industry, 2018
Patient groups with an interest in bleeding disorders believe innovation and the development of new treatments to be the most important contributions that pharma can make to improve the well-being of people living with haemophilia (or similar blood disorders). Around 70% of the bleeding-disorders patient groups participating in the 2018 survey regard pharma companies to be "Excellent" or "Good" at these activities (although levels of patient-group endorsement have declined slightly since 2016).
Bleeding-disorders patient groups say that only the biotechnology industry, among other healthcare industries, has a better corporate reputation than the pharma industry (presumably, since biotech is seen by these patient groups as more inventive than pharma).
So, how did the eight pharma companies perform at corporate reputation in 2018 (in the opinion of patient groups specialising in bleeding disorders)?
Ranking at corporate reputation is measured by patient groups familiar with a company.
Roche (Genentech in the US) was ranked overall 1st out of eight companies for corporate reputation in 2018 by bleeding-disorders patient groups claiming familiarity with it. This performance at corporate reputation represents a significant increase for Roche/Genentech on 2016, when the company was ranked only overall 8th out eight companies by patient groups specialising in bleeding disorders. In 2017, Roche was ranked 2nd.
Takeda (including Shire, acquired by Takeda in 2018-2019) was ranked overall 2nd out of eight companies for corporate reputation in 2018 by bleeding-disorders patient groups claiming familiarity with it. In 2017, Shire was ranked 5th out of nine companies; and, in 2016, 2nd out of eight companies.
Novo Nordisk was ranked overall 3rd out of eight companies for corporate reputation in 2018 by bleeding-disorders patient groups claiming familiarity with it - dropping from its position of 1st in both 2017 and 2016.
Given the importance that bleeding-disorders patient groups place on innovative capabilities, it is perhaps unsurprising that these patient groups judged the overall top-ranking company, Roche, as also best for a key individual indicator of corporate reputation - producing high-quality products (followed, in 2nd place for this indicator, by Takeda/Shire, and then by Novo Nordisk, in 3rd).
The importance of productive pharma/patient-group engagement
However, other factors can influence pharma-company standing among bleeding-disorders patient groups. As the table shows, a high level of outreach to bleeding-disorders patient groups does not automatically guarantee a company a commensurately high corporate reputation among this patient-group community.
In general, when a large percentage of bleeding-disorders patient groups stated that they had purely financial relationships with pharma companies, those companies were NOT seen by the patient groups as performing well at corporate reputation. Such results indicate that bleeding-disorders patient groups prefer their engagement with pharma companies to be active - in the form of assistance in project work, in training, or in other supportive functions (rather than merely being in receipt of financial donations).
For more information about this report, visit https://www.researchandmarkets.com/r/nit601.